Bio-Thera Solutions, trade code 688177.SH: Ustekinumab injection approved for market listing.

Bio-Thera Solutions (688177.SH) announced that the company has recently received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the marketing of Usymro (BAT2206, ustekinumab injection). The announcement stated that BAT2206 is a ustekinumab injection developed by Bio-Thera Solutions in accordance with the biosimilar guidelines of the China NMPA, US FDA, and European EMA. Ustekinumab is a fully human monoclonal antibody that targets the shared p40 subunit of interleukins IL-12 and IL-23. IL-12 and IL-23 are naturally produced cytokines that play a role in inflammation and immune response processes. Ustekinumab binds specifically and with high affinity to the p40 subunit, blocking its interaction with cell surface receptors, thereby disrupting the signaling and effects of IL-12 and IL-23.